Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial
在美国，一项首次人体I期随机试验，旨在评估V2特异性HIV-1广谱中和抗体PGDM1400LS在未感染HIV-1的人群中静脉或皮下输注的安全性、药代动力学和中和活性（HVTN 140/HPTN 101 A部分）：一项首次人体试验。
期刊:Lancet HIV
影响因子:13
doi:10.1016/S2352-3018(25)00012-8
Seaton, Kelly E; Paez, Carmen A; Yu, Chenchen; Karuna, Shelly T; Gamble, Theresa; Miner, Maurine D; Heptinstall, Jack; Zhang, Lu; Gao, Fei; Yacovone, Margaret; Spiegel, Hans; Dumond, Julie B; Anderson, Maija; Piwowar-Manning, Estelle; Dye, Bonnie; Tindale, India; Proulx-Burns, Lori; Trahey, Meg; Takuva, Simbarashe; Takalani, Azwidihwi; Bailey, Veronique C; Kalams, Spyros A; Scott, Hyman; Mkhize, Nonhlanhla N; Weiner, Joshua A; Ackerman, Margaret E; McElrath, M Juliana; Pensiero, Michael; Barouch, Dan H; Montefiori, David; Tomaras, Georgia D; Corey, Lawrence; Cohen, Myron S; Huang, Yunda; Mahomed, Sharana; Siegel, Marc; Kelley, Colleen F
